{
    "organizations": [],
    "uuid": "a245bad1649cfa9099a0e60c20dba357efa4863c",
    "author": "",
    "url": "https://www.reuters.com/article/brief-arbutus-and-roivant-launch-genevan/brief-arbutus-and-roivant-launch-genevant-sciences-with-platform-to-develop-broad-range-of-rna-therapeutics-for-genetic-diseases-idUSFWN1RO0Z0",
    "ord_in_thread": 0,
    "title": "BRIEF-Arbutus And Roivant Launch Genevant Sciences With Platform To Develop Broad Range Of RNA Therapeutics For Genetic Diseases",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 11 (Reuters) - Arbutus Biopharma Corp:-\n* LEADING PLATFORM TO DEVELOP BROAD RANGE OF RNA THERAPEUTICS FOR GENETIC DISEASES\n* GENEVANT WILL BE LED BY EXECUTIVE CHAIRMAN PARIS PANAYIOTOPOULOS, FORMER CEO OF ARIAD PHARMACEUTICALS THROUGH ITS 2017 ACQUISITION BY TAKEDA\n* GENEVANT AIMS FOR 5-10 PRODUCT CANDIDATES INTO CLINIC BY 2020 ACROSS RNAI, MRNA, GENE EDITING MODALITIES USING CO’S LNP, LIGAND CONJUGATE PLATFORMS\n* GENEVANT INTENDS TO ESTABLISH ITS U.S. HQ IN CAMBRIDGE, MASSACHUSETTS & ITS PRINCIPAL OPERATING CO IN BASEL, SWITZERLAND\n* UNDER TERMS OF AGREEMENT, ROIVANT SCIENCES WILL CONTRIBUTE $37.5 MLN IN TRANSACTION-RELATED SEED CAPITAL FOR GENEVANT\n* CO WILL RETAIN ENTIRETY OF ITS ROYALTY ENTITLEMENT ON COMMERCIALIZATION OF ALNYLAM PHARMACEUTICAL’S PATISIRAN\n* WILL RETAIN ALL RIGHTS TO LNP AND CONJUGATE DELIVERY PLATFORMS FOR HEPATITIS B VIRUS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-12T00:41:00.000+03:00",
    "crawled": "2018-04-12T00:54:22.006+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "arbutus",
        "biopharma",
        "corp",
        "leading",
        "platform",
        "develop",
        "broad",
        "range",
        "rna",
        "therapeutic",
        "genetic",
        "disease",
        "genevant",
        "led",
        "executive",
        "chairman",
        "paris",
        "panayiotopoulos",
        "former",
        "ceo",
        "ariad",
        "pharmaceutical",
        "acquisition",
        "takeda",
        "genevant",
        "aim",
        "product",
        "candidate",
        "clinic",
        "across",
        "rnai",
        "mrna",
        "gene",
        "editing",
        "modality",
        "using",
        "co",
        "lnp",
        "ligand",
        "conjugate",
        "platform",
        "genevant",
        "intends",
        "establish",
        "hq",
        "cambridge",
        "massachusetts",
        "principal",
        "operating",
        "co",
        "basel",
        "switzerland",
        "term",
        "agreement",
        "roivant",
        "science",
        "contribute",
        "mln",
        "seed",
        "capital",
        "genevant",
        "co",
        "retain",
        "entirety",
        "royalty",
        "entitlement",
        "commercialization",
        "alnylam",
        "pharmaceutical",
        "patisiran",
        "retain",
        "right",
        "lnp",
        "conjugate",
        "delivery",
        "platform",
        "hepatitis",
        "b",
        "virus",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}